Close Menu
Affy Warns of $20M Shortfall in Q3 Revenue
 
Affymetrix this week said that it expects a 21 percent drop in third-quarter revenues due to “increased competition for academic research funding and continued softness in industrial spending.”
 
The company said that total third-quarter 2008 revenue will be approximately $75 million. The company posted $95 million in revenue in the year-ago period and $84.7 million in the third quarter of 2006.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.